Windlas Biotech Q4 FY26: Record revenue, stronger cash flows, and the next capacity step

Windlas Biotech closed FY26 with its highest-ever revenue and another quarter of record execution. Consolidated net revenue from operations rose 19 percent year on year to 904 crore in FY26, while Q4 FY26 revenue increased 18 percent to 238 crore. Management highlighted this as the company’s 13th consecutive quarter of record revenue, achieved despite a moderate Indian Pharmaceutical Market volume growth of 2.7 percent in FY26.

Profitability showed a clear split between underlying operating performance and reported numbers due to a higher non-cash ESOP charge. For FY26, adjusted EBITDA was 121 crore with a margin of 13.4 percent, and adjusted PAT was 83 crore with a margin of 9.2 percent. Reported EBITDA was 105 crore with a margin of 11.6 percent, and reported PAT was 66 crore with a margin of 7.4 percent.

A growth year led by CDMO, with exports gaining momentum

The company’s Generic Formulations CDMO vertical remained the primary engine of scale. FY26 CDMO revenue grew 20 percent year on year to 664 crore, maintaining a 73 percent revenue mix. This business is positioned around branded generic products supplied to marketing companies, supported by Windlas’s end-to-end development and manufacturing capabilities.

Trade Generics and Institutional revenue grew 13 percent to 195 crore in FY26 and contributed 22 percent of revenues. In Q4 FY26, this segment was largely flat at 46 crore. Management and participants discussed a codeine-related product discontinuity that impacted the trade generics business over recent quarters, along with the inherently lumpy nature of institutional tender supplies.

Exports, while still only 5 percent of revenue, showed the highest percentage growth. FY26 export revenue rose 40 percent to 46 crore, and Q4 exports increased 67 percent year on year to 17 crore. Management attributed the improving trend to the payoff from regulatory approvals and product registrations pursued over multiple years, while reiterating that export markets typically have longer lead times.

Note: Adjusted metrics exclude non-cash ESOP expenses (FY26 ESOP expense was 17 crore).

Cash generation and capital allocation stayed in focus

One of the most notable aspects of FY26 was the company’s cash flow conversion and liquidity position. Net cash from operating activities was 105 crore for FY26, and management reported net liquidity of 251 crore with the company being net debt free. The presentation also highlighted a 105 crore cash generated from operations for FY26.

Capital allocation included both growth investment and shareholder returns. The company completed a buyback of up to 4,70,000 equity shares (about 2.23 percent of total equity shares) aggregating to about 47 crore at 1,000 per share. Promoters did not participate, and the bought-back shares were extinguished. In addition, the Board proposed a dividend of about 13 crore, equivalent to 6.30 per share for FY26. The company reiterated its aim to maintain a dividend payout ratio as near as possible to 20 percent of consolidated profit after tax, subject to capital needs and cash flows.

Capacity, compliance, and the next leg of scale

The company’s near-term capacity narrative is centered on Plant-6, which management said has achieved mechanical completion, with commercialization targeted by H1 FY27. In the concall, management also stated that excluding injectables, the company can deliver about 1,000 crore revenue with Plant-6, while injectables is about 100 crore, with further upside possible through efficiency improvements as operations stabilize.

Injectables continue to be positioned as a key dosage-form expansion. During FY26, Plant-5 (injectable facility) received a GMP certificate from the Philippines. Management said the injectables business is scaling and catching up versus earlier internal timelines. However, when asked about EU-GMP timelines, management did not provide a timeline and explicitly declined to comment.

On regulatory and compliance capability, management emphasized the increasing scrutiny on quality systems, including evolving requirements under Schedule M. They stated the company undergoes around 70 to 80 audits per year across facilities and described investments in electronic learning management for SOP training, authorization testing, and continuous skill building. This matters for a CDMO business where customers assess not just product quality but also system maturity and compliance culture.

Takeaways from Q4 and FY26

Windlas entered FY27 with a clear operating base: a large and growing CDMO business, a trade generics vertical that management still views as strategically relevant despite near-term product discontinuities, and exports showing stronger traction after multi-year regulatory groundwork.

The core investor watchpoints from here are execution on Plant-6 commercialization in H1 FY27, continued ramp-up of injectables, and the sustainability of adjusted margins given ESOP costs will continue to flow through the reported profit and loss account as per the company’s disclosed schedule. With strong operating cash flows, net liquidity, and disciplined capital allocation actions such as buyback and dividend, the company has positioned itself to pursue growth while maintaining balance sheet resilience.